Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11617
Peer-review started: July 14, 2022
First decision: August 1, 2022
Revised: August 19, 2022
Accepted: September 21, 2022
Article in press: September 21, 2022
Published online: November 6, 2022
There is no established treatment for primary pulmonary lymphoepithelioma-like carcinoma (LELC) until now.
In this study, the patient responded well to sintilimab combined with paclitaxel and carboplatin, showing no obvious side effects. Meantime, the values of carbohydrate antigen 15-3 (CA15-3) and carbohydrate antigen 72-4 (CA72-4) gradually returned to normal.
Immunotherapy combined with chemotherapy in advanced-stage LELC may be more effective than immunotherapy or chemotherapy alone. CA15-3 and CA72-4 are biomarkers for evaluating therapeutic effects for LELC.
Core Tip: Herein, we present the case of a lymphoepithelioma-like carcinoma (LELC) patient who was successfully treated with sintilimab combined with paclitaxel and carboplatin. Recent literature on LELC is also reviewed and discussed for future avenues for LELC research.